ライフサイエンスコーパス: neuralgia

1 and account for the development of herpetic neuralgia.

2 multiple sclerosis patients with trigeminal neuralgia.

3 r, and had an uncomplicated recovery without neuralgia.

4 t at risk of prolonged pain and postherpetic neuralgia.

5 y little pain, and there was no postherpetic neuralgia.

6 nt of chickenpox, shingles, and postherpetic neuralgia.

7 l nerve for medically intractable trigeminal neuralgia.

8 king in patients with presumed genitofemoral neuralgia.

9 effective for the diagnosis of genitofemoral neuralgia.

10 of Carbamazepine in treatment of Trigeminal Neuralgia.

11 er, which may be complicated by postherpetic neuralgia.

12 ndrome, Achilles tendinitis and medial nerve neuralgia.

13 ccount for the development of acute herpetic neuralgia.

14 shown striking similarities with trigeminal neuralgia.

15 gical concept of SUNCT, SUNA, and trigeminal neuralgia.

16 ical basis between SUNCT/SUNA and trigeminal neuralgia.

17 tial of EMA401 in patients with postherpetic neuralgia.

18 uritis with classical symptoms of peripheral neuralgia.

19 , which is often complicated by postherpetic neuralgia.

20 events such as xerophthalmia and trigeminal neuralgia.

21 or definitive management of chronic inguinal neuralgia.

22 thophysiology of pre- and typical trigeminal neuralgia.

23 d HZ severity and occurrence of postherpetic neuralgia.

24 d can be further complicated by postherpetic neuralgia.

25 th reduced HZ severity and less postherpetic neuralgia.

26 ed pain relief in patients with postherpetic neuralgia.

27 y a critical role in the genesis of herpetic neuralgia.

28 dults against herpes zoster and postherpetic neuralgia.

29 ed noninvasively in patients with trigeminal neuralgia.

30 ive pain score in patients with postherpetic neuralgia.

31 erpes zoster and 70-88% against postherpetic neuralgia.

32 complaints following surgery for trigeminal neuralgia.

33 ions of the surgical treatment of trigeminal neuralgia.

34 lodynia in this animal model of postherpetic neuralgia.

35 end point was the incidence of postherpetic neuralgia.

36 the unique clinical features of postherpetic neuralgia.

37 lt from the surgical treatment of trigeminal neuralgia.

38 nto the potential mechanisms of postherpetic neuralgia.

39 o 0.67 [0.61-0.74]) and 38% for postherpetic neuralgia (0.62 [0.50-0.79]).

40 NS infections, 12 (CI: 5, 13); post-herpetic neuralgia, 11 (CI: 6, 17); and major neurological injuri

41 bo recipients) and 107 cases of postherpetic neuralgia (27 among vaccine recipients and 80 among plac

42 ts with and 16 subjects without postherpetic neuralgia after unilateral shingles.

43 ster and 3300 fewer episodes of postherpetic neuralgia among 5.5 million eligible individuals in the

44 orbidity from herpes zoster and postherpetic neuralgia among older adults.

45 y, or both of herpes zoster and postherpetic neuralgia among older adults.

46 In postherpetic neuralgia and complex regional pain syndrome, for exampl

47 ms involved in the genesis of acute herpetic neuralgia and open new avenues for its control.

48 ultations for herpes zoster and postherpetic neuralgia, and aggregated these data to estimate vaccine

49 the neuro-ophthalmic features of trigeminal neuralgia, and detail the neuro-ophthalmic side effects

50 Existing treatments for postherpetic neuralgia, and for neuropathic pain in general, are limi

51 66.5% to 35.4% for incidence of postherpetic neuralgia, and from 51.3% to 21.1% for incidence of HZ,

52 ith autonomic symptoms (SUNA) and trigeminal neuralgia are considered different disorders, thus group

53 hysiological mechanisms involved in herpetic neuralgia are not totally elucidated.

54 at persistent RSD/CRPS-I is a post-traumatic neuralgia associated with distal degeneration of small-d

55 complications, namely incisional hernias and neuralgia at the trocar sites, which can potentially be

56 .001), reduced the incidence of postherpetic neuralgia by 66.5 percent (P<0.001), and reduced the inc

57 Trigeminal neuralgia can occur in association with a range of other

58 s or open surgical procedures for trigeminal neuralgia can result in corneal anesthesia, neurotrophic

59 ly) provides superior relief of postherpetic neuralgia compared with placebo at the end of 28 days of

60 reating diabetic neuropathy and postherpetic neuralgia compared with placebo, gabapentin and pregabal

61 incidence of herpes zoster and postherpetic neuralgia consultations.

62 TNF, via TNFR1, mediates herpetic neuralgia development through downregulation of the inwa

63 al trials for the treatment of post-herpetic neuralgia, diabetic peripheral neuropathy, generalized a

64 io 0.65 [95% 0.60-0.72]) and of postherpetic neuralgia fell by 50% (0.50 [0.38-0.67]).

65 were aged 18-90 years, had had postherpetic neuralgia for at least 6 months, and had an average base

66 al option for management of their trigeminal neuralgia for many years.

67 iew of surgical interventions for trigeminal neuralgia found not a single trial of what is becoming t

68 The group with postherpetic neuralgia had a mean density of 339 +/- 97 neurites/mm2

69 overlap between SUNCT, SUNA, and trigeminal neuralgia has challenged this traditional view.

70 icacy of BIIB074 in patients with trigeminal neuralgia in a phase 2a study.

71 ation of BIIB074 in patients with trigeminal neuralgia in future clinical trials.

72 treatment of herpes zoster and postherpetic neuralgia in immunocompetent older adults are reviewed,

73 in preventing herpes zoster and postherpetic neuralgia in immunocompetent older adults.

74 onsible for the spontaneous remission of the neuralgia in some patients.

75 incidence of herpes zoster and postherpetic neuralgia in this population.

76 Other causes of trigeminal neuralgia in which demyelination is involved or implicat

77 d severity of herpes zoster and postherpetic neuralgia increase with age in association with a progre

78 ities available for patients with trigeminal neuralgia intolerable or resistant to medical therapy.

79 Trigeminal Neuralgia is a disorder that is characterized with elect

80 Postherpetic neuralgia is not prevented by early systemic antivirals

81 ontrol.SIGNIFICANCE STATEMENT Acute herpetic neuralgia is the most important symptom of herpes zoster

82 Herpetic neuralgia is the most important symptom of herpes zoster

83 Current standard of care for trigeminal neuralgia is treatment with the sodium channel blockers

84 e is now persuasive evidence that trigeminal neuralgia is usually caused by demyelination of trigemin

85 ted in the painful condition of postherpetic neuralgia, is regulated by the cytoplasmic domains of gB

86 cause chronic neuropathic pain (postherpetic neuralgia) long after skin lesions heal.

87 er, which may be complicated by postherpetic neuralgia, myelitis, meningoencephalitis, and VZV vascul

88 -89 years for herpes zoster and postherpetic neuralgia occurring between Oct 1, 2005, and Sept 30, 20

89 atients (aged 22-89 years) with postherpetic neuralgia of at least 6 months' duration from 29 centres

90 Patients with postherpetic neuralgia often have an increased sensitivity to a tacti

91 eripheral nervous system (e.g. post-herpetic neuralgia or diabetic neuropathy) or to the central nerv

92 al manifestations and etiology of trigeminal neuralgia, outline the neuro-ophthalmic features of trig

93 Thus, the pathophysiology of postherpetic neuralgia pain may involve a new bilateral mechanism.

94 A postherpetic-neuralgia patient abruptly discontinued pregabalin.

95 Herpes zoster (HZ) and postherpetic neuralgia (PHN) cause significant morbidity in older adu

96 tions of current treatments for postherpetic neuralgia (PHN) have led to the investigation of localis

97 Postherpetic neuralgia (PHN) is a common complication of shingles tha

98 Postherpetic neuralgia (PHN) is a syndrome of often intractable neuro

99 Post-herpetic neuralgia (PHN) is the most significant complication of

100 that zoster vaccination reduces postherpetic neuralgia (PHN) risk by reducing herpes zoster (HZ) occu

101 ferences in antiviral efficacy, postherpetic neuralgia (PHN) risk, and other illness parameters.

102 al reactivation are at risk for postherpetic neuralgia (PHN), a painful and long-lasting complication

103 burden of illness, incidence of postherpetic neuralgia (PHN), and incidence of HZ were assessed for t

104 ted with herpes zoster (HZ) and postherpetic neuralgia (PHN), intentions for recommending the HZ vacc

105 often debilitating pain called postherpetic neuralgia (PHN), which can last for months after the dis

106 loping the painful condition of postherpetic neuralgia (PHN), which has been difficult to treat becau

107 ir treatment on the duration of postherpetic neuralgia (PHN), which was defined as pain persisting af

108 ding ophthalmic zoster (OZ) and postherpetic neuralgia (PHN).

109 S. adults, many of whom develop postherpetic neuralgia (PHN).

110 serious consequences, notably post-herpetic neuralgia (PHN).

111 e to acute and chronic pain, or postherpetic neuralgia (PHN).

112 of zoster (group 1), zoster and postherpetic neuralgia (PHN; group 2), or no history of zoster (group

113 t patients with vessel-associated trigeminal neuralgia, probably because the resulting separation of

114 s aged 18-80 years with confirmed trigeminal neuralgia received open-label, BIIB074 150 mg three time

115 ded peripheral visual field loss, trigeminal neuralgia, recurrent Bell's palsy, and pulsatile tinnitu

116 idence on whether SUNCT, SUNA and trigeminal neuralgia should be considered separate entities or vari

117 in turn mediates the development of herpetic neuralgia through downregulation of the inwardly rectify

118 eral surgical procedures to treat trigeminal neuralgia (tic douloureux) are available, but most repor

119 However little is known about how trigeminal neuralgia (TN), a condition in which trigeminal stimulat

120 lia that account for the genesis of herpetic neuralgia using a murine model of Herpes Simplex Virus T

121 confirmed intractable unilateral trigeminal neuralgia were measured before treatment with gamma knif

122 safe and effective treatment for trigeminal neuralgia, with a high rate of long-term success.